adenine has been researched along with Herpes Genitalis in 21 studies
Herpes Genitalis: Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models." | 7.78 | Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. ( Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM, 2012) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models." | 3.78 | Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. ( Herold, BC; Huber, AM; Kiser, PF; Mesquita, PM; Rastogi, R; Segarra, TJ; Teller, RS; Torres, NM, 2012) |
| " Previous studies have demonstrated an increased susceptibility to genital herpes in mice following repeated applications of nonoxynol-9 (N-9)." | 3.75 | Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. ( Cheshenko, N; Fakioglu, E; Herold, BC; Keller, MJ; Mesquita, PM; Wilson, SS, 2009) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 18 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thurman, AR | 1 |
| Schwartz, JL | 1 |
| Ravel, J | 1 |
| Gajer, P | 1 |
| Marzinke, MA | 1 |
| Yousefieh, N | 1 |
| Anderson, SM | 1 |
| Doncel, GF | 1 |
| Nixon, B | 1 |
| Jandl, T | 1 |
| Teller, RS | 2 |
| Taneva, E | 1 |
| Wang, Y | 1 |
| Nagaraja, U | 1 |
| Kiser, PF | 2 |
| Herold, BC | 3 |
| Terris-Prestholt, F | 1 |
| Foss, AM | 1 |
| Cox, AP | 1 |
| Heise, L | 1 |
| Meyer-Rath, G | 1 |
| Delany-Moretlwe, S | 1 |
| Mertenskoetter, T | 1 |
| Rees, H | 1 |
| Vickerman, P | 1 |
| Watts, CH | 1 |
| Celum, C | 1 |
| Morrow, RA | 1 |
| Donnell, D | 1 |
| Hong, T | 1 |
| Hendrix, CW | 1 |
| Thomas, KK | 1 |
| Fife, KH | 1 |
| Nakku-Joloba, E | 1 |
| Mujugira, A | 1 |
| Baeten, JM | 1 |
| Shankar, GN | 1 |
| Alt, C | 1 |
| Abdool Karim, SS | 4 |
| Abdool Karim, Q | 4 |
| Kharsany, AB | 1 |
| Baxter, C | 1 |
| Grobler, AC | 1 |
| Werner, L | 1 |
| Kashuba, A | 1 |
| Mansoor, LE | 1 |
| Samsunder, N | 2 |
| Mindel, A | 1 |
| Gengiah, TN | 2 |
| Feder, HM | 1 |
| Agut, H | 1 |
| Burrel, S | 1 |
| Boutolleau, D | 1 |
| Baang, J | 1 |
| Wilson, SS | 1 |
| Cheshenko, N | 1 |
| Fakioglu, E | 1 |
| Mesquita, PM | 2 |
| Keller, MJ | 1 |
| Andrei, G | 1 |
| Lisco, A | 1 |
| Vanpouille, C | 1 |
| Introini, A | 1 |
| Balestra, E | 1 |
| van den Oord, J | 1 |
| Cihlar, T | 1 |
| Perno, CF | 1 |
| Snoeck, R | 1 |
| Margolis, L | 1 |
| Balzarini, J | 1 |
| Moss, JA | 1 |
| Malone, AM | 1 |
| Smith, TJ | 1 |
| Kennedy, S | 1 |
| Kopin, E | 1 |
| Nguyen, C | 1 |
| Gilman, J | 1 |
| Butkyavichene, I | 1 |
| Vincent, KL | 1 |
| Motamedi, M | 1 |
| Friend, DR | 2 |
| Clark, MR | 1 |
| Baum, MM | 1 |
| Rastogi, R | 1 |
| Segarra, TJ | 1 |
| Torres, NM | 1 |
| Huber, AM | 1 |
| Naranbhai, V | 2 |
| Altfeld, M | 2 |
| Ndung'u, T | 1 |
| Carr, WH | 2 |
| Durgiah, R | 1 |
| Sibeko, S | 1 |
| Vibholm, L | 1 |
| Reinert, LS | 1 |
| Søgaard, OS | 1 |
| Paludan, SR | 1 |
| Østergaard, L | 1 |
| Tolstrup, M | 1 |
| Melchjorsen, J | 1 |
| Cohen, J | 1 |
| Bestman-Smith, J | 1 |
| Boivin, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone[NCT02235662] | Phase 1 | 86 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples[NCT00557245] | Phase 3 | 4,758 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa[NCT00441298] | Phase 2 | 889 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring[NCT02006264] | Phase 1 | 30 participants (Actual) | Interventional | 2013-11-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Infant outcomes measured as the number of live-born infants born to female participants taking study drug that had any congenital anomalies. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | Number of live-born infants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 4 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 4 |
| Placebo | 5 |
The slope of the linear model of the growth of infants (head circumference) during the entirety of follow-up. The head circumference of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month. (NCT00557245)
Timeframe: up to 12 months
| Intervention | z-score difference per study month (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | -0.057 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | -0.005 |
| Placebo | -0.079 |
The efficacy of once daily PrEP in preventing HIV-1 acquisition among uninfected heterosexuals in HIV-1 discordant partnerships, measured by calculating the HIV incidence per 100 person-years in each of three arms. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | events per 100 person years (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 0.65 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0.50 |
| Placebo | 1.99 |
The slope of the linear model of the growth of infants (length) during the entirety of follow-up. The length of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month. (NCT00557245)
Timeframe: up to 12 months
| Intervention | z-score difference per study month (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | -0.006 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0.036 |
| Placebo | -0.033 |
"Prevalence of STIs measured as the number of participants with a positive test result for N. gonorrhoeae, C. trachomatis, or T. vaginalis during follow-up. Participants were tested for STIs at annual follow-up visits and at intervening visits at which the participant presented with symptoms of an STI. Assessment for symptomatic sexually transmitted infections was conducted quarterly.~N. gonorrhoeae and C. trachomatis testing were by APTIMA Combo 2 (Gen-Probe) or COBAS Amplicor (Roche Diagnostics). T. vaginalis testing was by APTIMA TV TMA (Gen-Probe) or In Pouch TV (Biomed Diagnostics)." (NCT00557245)
Timeframe: Up to 36 months
| Intervention | participants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 102 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 76 |
| Placebo | 85 |
Safety of daily TDF or FTC/TDF among HIV-1 uninfected individuals randomized to TDF or FTC/TDF compared to those randomized to placebo measured as the number of participants with Serious Adverse Events (SAEs) during follow-up. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | Participants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 118 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 115 |
| Placebo | 118 |
"HIV-1 resistance as measured by the number of seroconverters who had an HIV-1 reverse transcriptase mutation (K65R, K70E, M184I, or M184V) conferring resistance to TDF or FTC. These mutation types were pre-defined. Plasma samples for resistance testing were collected at the visit seroconversion was first detected and again at a visit within 1 month of seroconversion. Mutations detected at either of those visits are reported.~Both seroconverters found to have a resistance mutation had been HIV infected at enrollment (TDF arm: n=1; FTC-TDF arm: n=1)." (NCT00557245)
Timeframe: Up to 36 months
| Intervention | Participants (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 1 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| Placebo | 0 |
Sexual risk behavior of participants, measured as the percentage of visits when participants reported having unprotected sex during follow-up. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | percentage of visits (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 14 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 13 |
| Placebo | 13 |
Adherence to study medication as assessed by pill count at follow-up visits. We assessed the total number of doses taken of the total dispensed doses. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | percentage of doses taken of dispensed (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | 97 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 97 |
| Placebo | 97 |
The slope of the linear model of the growth of infants (weight) during the entirety of follow-up. The weight of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month. (NCT00557245)
Timeframe: up to 12 months
| Intervention | z-score difference per study month (Number) |
|---|---|
| Tenofovir Disoproxil Fumarate (TDF) | -0.021 |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0.009 |
| Placebo | -0.056 |
Adherence to study drug measured as the percentage of visits when participants reported missing 1) any dose of study drug in the prior month and 2) 2 or more consecutive doses of study drug. (NCT00557245)
Timeframe: Up to 36 months
| Intervention | percentage of visits (Number) | |
|---|---|---|
| Missed any doses | Missed 2+ consecutive doses | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 15 | 4 |
| Placebo | 15 | 4 |
| Tenofovir Disoproxil Fumarate (TDF) | 15 | 4 |
Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product (NCT02006264)
Timeframe: 14 days of vaginal ring use
| Intervention | Adverse events (Number) |
|---|---|
| TDF Intravaginal Ring | 7 |
| Placebo Intravaginal Ring | 1 |
Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period (NCT02006264)
Timeframe: 14 days of vaginal ring use
| Intervention | Adverse events (Number) |
|---|---|
| TDF Intravaginal Ring | 2 |
| Placebo Intravaginal Ring | 0 |
TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use
| Intervention | ng/mg (Median) |
|---|---|
| TDF Intravaginal Ring | 5.4 |
TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use
| Intervention | fmol/mg (Median) |
|---|---|
| TDF Intravaginal Ring | 120 |
TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
| Intervention | ng/mL (Median) | ||||
|---|---|---|---|---|---|
| C-max CVF VAG TDF | C-max CVF ECX TDF | C-max CVF VAG TFV | C-max CVF ECX TFV | C-max Plasma TFV | |
| TDF Intravaginal Ring | 240000 | 210000 | 91000 | 85000 | 1.9 |
TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
| Intervention | h (Median) | ||||
|---|---|---|---|---|---|
| T-max CVF VAG TDF | T-max CVF ECX TDF | T-max CVF VAG TFV | T-max CVF ECX TFV | T-max Plasma TFV | |
| TDF Intravaginal Ring | 6 | 5 | 14 | 7 | 14 |
TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
| Intervention | ngxd/mL (Median) | ||||
|---|---|---|---|---|---|
| AUC0-14 (days 0-14), CVF VAG TDF | AUC0-14 (days 0-14), CVF ECX TDF | AUC0-14 (days 0-14), CVF VAG TFV | AUC0-14 (days 0-14), CVF ECX TFV | AUC0-14 (days 0-14), Plasma TFV | |
| TDF Intravaginal Ring | 2000000 | 1300000 | 1100000 | 970000 | 9.4 |
1 review available for adenine and Herpes Genitalis
| Article | Year |
|---|---|
Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission.
Topics: Adenine; Administration, Intravaginal; Anti-Infective Agents; Antiviral Agents; Biopharmaceutics; Co | 2012 |
3 trials available for adenine and Herpes Genitalis
| Article | Year |
|---|---|
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Contraceptive Agents, Hormonal; Contraceptive Dev | 2019 |
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Topics: Adenine; Administration, Oral; Adult; Anti-Retroviral Agents; Antiviral Agents; Deoxycytidine; Drug | 2014 |
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Topics: Adenine; Administration, Intravaginal; Adult; Double-Blind Method; Female; Follow-Up Studies; Gels; | 2015 |
17 other studies available for adenine and Herpes Genitalis
| Article | Year |
|---|---|
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
Topics: Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Contraceptive Devices, Female; Dis | 2014 |
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Topics: Adenine; Anti-HIV Agents; Circumcision, Male; Cost-Benefit Analysis; Female; Forecasting; Herpes Gen | 2014 |
Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
Topics: Acrylic Resins; Acyclovir; Adenine; Animals; Anti-Infective Agents; Chlorocebus aethiops; Disease Mo | 2014 |
Tenofovir Gel to Prevent HSV-2 Infection.
Topics: Adenine; Female; Herpes Genitalis; Herpesvirus 2, Human; Humans; Organophosphonates; Reverse Transcr | 2015 |
Tenofovir Gel to Prevent HSV-2 Infection.
Topics: Adenine; Female; Herpes Genitalis; Herpesvirus 2, Human; Humans; Organophosphonates; Reverse Transcr | 2015 |
Tenofovir Gel to Prevent HSV-2 Infection.
Topics: Adenine; Female; Herpes Genitalis; Herpesvirus 2, Human; Humans; Organophosphonates; Reverse Transcr | 2015 |
Pericoital application of tenofovir gel reduced risk for herpes simplex virus type 2 in HIV-negative women.
Topics: Adenine; Female; Herpes Genitalis; Herpesvirus 2, Human; Humans; Organophosphonates; Reverse Transcr | 2015 |
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-Infective Agents; Antiviral Agents; Biomarkers; | 2009 |
Prevention. Study reveals that vaginal gel reduces HIV, herpes.
Topics: Adenine; Female; Gels; Herpes Genitalis; HIV Infections; Humans; Organophosphonates; Reverse Transcr | 2010 |
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.
Topics: Adenine; Administration, Topical; Animals; Anti-Infective Agents; Cells, Cultured; DNA-Directed DNA | 2011 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delaye | 2012 |
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.
Topics: Adenine; Antiviral Agents; Cell Culture Techniques; Chemoprevention; Contraceptive Devices, Female; | 2012 |
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial.
Topics: Adenine; Administration, Topical; Adult; Anti-HIV Agents; Case-Control Studies; CD4-Positive T-Lymph | 2012 |
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Topics: Adenine; Adult; Anti-HIV Agents; Avian Proteins; Case-Control Studies; Coinfection; Cytokines; Disea | 2012 |
Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
Topics: Adenine; Administration, Topical; Animals; Anti-Infective Agents; Antiviral Agents; Cells, Cultured; | 2012 |
HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Topics: Acyclovir; Adenine; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Antiviral Agents; Bup | 2005 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |